EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

Antiretroviral Activity, Pharmacokinetics, and Safety of MK-8527, an Oral Nucleoside Reverse Transcriptase Translocation Inhibitor, in Adults With HIV-1 Who Had Not Previously Taken Antiretroviral Agents: Results From 2 Open-Label, Phase 1 Studies

Russ P Carstens iD, Yash Kapoor iD, Ryan C Vargo, Arinjita Bhattacharyya, Graigory Garrett, Caroline Cilissen, Adedayo Adedoyin, Xiaowei Zang iD, Jean-Francois Denef, Carlien Leyssens, Tom Reynders, Liliana Preotescu und 8 weitere

Clinical Infectious Diseases · 20.05.2026 · 82 (5) · e984-e991

DOI: 10.1093/cid/ciag135 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Infectious Diseases, online erschienen am 14.03.2026. Verfasst von Russ P Carstens und 19 weiteren Autor:innen. Beteiligte Einrichtung: MRL, Merck & Co., Inc., Rahway, New Jersey, USA. Hauptthemen laut MEDLINE: HIV Infections, HIV-1, Anti-HIV Agents, Reverse Transcriptase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Sharp & Dohme LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

MK-8527 is a novel oral nucleoside reverse transcriptase translocation inhibitor under clinical development as HIV-1 (HIV) prevention. Two Phase 1 single-dose monotherapy studies were conducted to evaluate antiretroviral activity, pharmacokinetics (PK), and safety of MK-8527 in adults with HIV who had not previously taken antiretroviral agents.

Methods

In 2 Phase 1 studies, participants received a single oral dose of MK-8527 (0.25, 0.5, 1, 3, or 10 mg). Reduction in viral load (measured as log10 plasma HIV RNA copies/mL at 7 days post-dose), PK of plasma MK-8527 through 7 days, intracellular MK-8527-triphosphate (TP, the active form of MK-8527) through 28 days, exposure–response relationship, and safety through 28 days were assessed. Adverse events were descriptively summarized.

Results

In total, 37 participants completed the studies. After single doses of MK-8527 0.5 to 10 mg, the mean decrease in HIV RNA at 7 days-post dose was ≥1.0 log10 copies/mL. The inhibitory quotient (defined as the ratio of MK-8527-TP concentration at 168 hours post-dose [C168] to the mean intracellular concentration of MK-8527-TP at the half-maximal inhibitory concentration [IC50]) exceeded 3 at single doses of ≥0.5 mg. MK-8527 at all dose levels was well tolerated, with a limited number of mild or moderate adverse events that were determined by investigators to be unrelated to the study treatment.

Conclusions

In adults with HIV who had not previously taken antiretroviral agents, single doses of MK-8527 as low as 0.5 mg achieved ≥1.0 log10 decreases in HIV RNA at 7 days post-dose administration. Clinical Trials Registration www.clinicaltrials.gov NCT03615183, NCT05494736

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsHIV-1Anti-HIV AgentsReverse Transcriptase InhibitorsHumansAdultFemaleMaleMiddle AgedViral LoadAdministration, OralYoung AdultRNA, ViralAdolescentTreatment OutcomeDeoxyadenosines

Stichwörter der Autor:innen

HIV-1antiretroviralnucleoside reverse transcriptase translocation inhibitorpharmacokineticssafety

Substanzen

Anti-HIV AgentsReverse Transcriptase InhibitorsislatravirRNA, ViralDeoxyadenosines

Autor:innen und Institutionen

  • MRL, Merck & Co., Inc., Rahway, New Jersey, USA.
  • MRL, MSD Belgium, Brussels, Belgium.
  • Department of Internal Medicine, National Institute for Infectious Diseases "Prof. Dr. Matei Bals," Bucharest, Romania.
  • LGBT+ Health Division/GSH Trials Unit, Desmond Tutu Health Foundation, Cape Town, South Africa.
  • Clinical HIV Research Unit, University of Witwatersrand, Helen Joseph Hospital, Johannesburg, South Africa.
  • Research and Development, Josha Research, Bloemfontein, South Africa.

ORCID-Profile: Russ P Carstens, Yash Kapoor, Xiaowei Zang, Richard Kaplan, Anca Streinu-Cercel

Förderung

  • Merck Sharp & Dohme LLC

Zitieren

APA

Carstens, R. P., Kapoor, Y., Vargo, R. C., Bhattacharyya, A., Garrett, G., Cilissen, C., Adedoyin, A., Zang, X., Denef, J. F., Leyssens, C., Reynders, T., Preotescu, L., Kaplan, R., Rassool, M., Lombaard, J., Streinu-Cercel, A., Matthews, R. P., Stoch, S. A., Iwamoto, M., & Gillespie, G. L. (2026). Antiretroviral Activity, Pharmacokinetics, and Safety of MK-8527, an Oral Nucleoside Reverse Transcriptase Translocation Inhibitor, in Adults With HIV-1 Who Had Not Previously Taken Antiretroviral Agents: Results From 2 Open-Label, Phase 1 Studies. Clinical Infectious Diseases, 82(5), e984-e991. https://doi.org/10.1093/cid/ciag135

Vancouver

Carstens RP, Kapoor Y, Vargo RC, Bhattacharyya A, Garrett G, Cilissen C, et al. Antiretroviral Activity, Pharmacokinetics, and Safety of MK-8527, an Oral Nucleoside Reverse Transcriptase Translocation Inhibitor, in Adults With HIV-1 Who Had Not Previously Taken Antiretroviral Agents: Results From 2 Open-Label, Phase 1 Studies. Clinical Infectious Diseases. 2026;82(5):e984-e991. doi:10.1093/cid/ciag135

BibTeX
@article{Carstens2026,
  author = {Carstens, Russ P and Kapoor, Yash and Vargo, Ryan C and Bhattacharyya, Arinjita and Garrett, Graigory and Cilissen, Caroline and Adedoyin, Adedayo and Zang, Xiaowei and Denef, Jean-Francois and Leyssens, Carlien and Reynders, Tom and Preotescu, Liliana and Kaplan, Richard and Rassool, Mohammed and Lombaard, Johannes and Streinu-Cercel, Anca and Matthews, Randolph P and Stoch, S Aubrey and Iwamoto, Marian and Gillespie, Gillian L},
  title = {Antiretroviral Activity, Pharmacokinetics, and Safety of MK-8527, an Oral Nucleoside Reverse Transcriptase Translocation Inhibitor, in Adults With HIV-1 Who Had Not Previously Taken Antiretroviral Agents: Results From 2 Open-Label, Phase 1 Studies},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  volume = {82},
  number = {5},
  pages = {e984--e991},
  doi = {10.1093/cid/ciag135}
}
Kostenlos starten →